Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range
This article was originally published in The Pink Sheet Daily
Executive Summary
$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.
You may also be interested in...
Alimera To Resubmit Iluvien With No New Studies
FDA has twice rebuffed Alimera’s marketing application for the intravitreal insert, which releases a corticosteroid to treat chronic diabetic macular edema, citing a bad risk/benefit balance. But after meeting with the agency in the second quarter, the company is confident a reanalysis of pivotal data will satisfy the agency.
Alimera To Resubmit Iluvien With No New Studies
FDA has twice rebuffed Alimera’s marketing application for the intravitreal insert, which releases a corticosteroid to treat chronic diabetic macular edema, citing a bad risk/benefit balance. But after meeting with the agency in the second quarter, the company is confident a reanalysis of pivotal data will satisfy the agency.
PregLem Weighs Financing Options Well Ahead Of Uterine Fibroid Drug Launch
Esmya, an oral therapy being developed for symptomatic uterine fibroids, showed non-inferiority to GnRH agonists in a Phase III study.